Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shire secures FDA approval for primary immunodeficiency drug
CUVITRU is a treatment for patients with primary immunodeficiency (PI), a group of more than 300 genetic disorders in which part of the body’s immune system is missing
CUVITRU is a treatment for patients with primary immunodeficiency (PI), a group of more than 300 genetic disorders in which part of the body’s immune system is missing
Depression is one of the most common mental health disorders in the United States, as an estimated one in 15 adults (6.7%) experience at least one major depressive
Alliance acquired UK rights to Diclectin in January 2015 and this additional agreement secures rights to launch the product in a further nine EU countries including Germany, France
These two large outcome trials will help to define the potential role of dapagliflozin in the management of chronic kidney disease and chronic heart failure respectively, in people
Biological therapeutics represented seven of the top ten best selling drugs of 2015, and they feature extensively in developmental pipelines. Access to bioproduction cell lines for their manufacture
MacroGenics has regained the worldwide rights to MGD010, a bispecific molecule targeting CD32B and CD79B. Takeda’s decision comes earlier than the predefined expiration of its option exercise period
"XmAb14045 is a bispecific antibody that engages the immune system against AML," said Paul Foster, M.D., chief medical officer at Xencor. "Built on the scaffold of Xencor's XmAb
The products are currently sold at several large retailers including Rite-Aid, CVS, Wal-Mart and K-Mart. As part of the transaction, all assets from Dermasilk Brands, Inc. will be
The combination of EPAM’s strong Big Data solutions practice and Sinequa’s unique Cognitive Search and Analytics platform offers customers the ability to gain quick, actionable insights from their
CHO cells are commonly used in the manufacture of biologics. Merck's new Centinel technology targets genes which play a role in MVM susceptibility. Viral contaminations like MVM can